Promising Drug Combination Shows New Hope for Leukemia Patients Resistant to Treatment

A groundbreaking drug combination could offer new hope to leukemia patients who don’t respond to conventional therapies, according to research from Oregon Health and Science University.

The team analyzed samples from over 300 patients with acute myeloid leukemia (AML), one of the most common and aggressive forms of leukemia that affects more than 20,000 Americans annually.

Researchers discovered that pairing venetoclax, a standard leukemia treatment, with palbociclib, typically used for breast cancer, created significantly stronger and more durable anti-leukemia effects than venetoclax alone. These findings were validated in both human tissue samples and mouse models carrying human leukemia cells.

“The data show that this drug regimen may be especially effective in patients whose tumors exhibit features that cause resistance to the current standard of care, frontline therapies,” explained Jeffrey Tyner, professor of cell, developmental and cancer biology at OHSU’s School of Medicine and the Knight Cancer Institute.

The discovery came about through extensive testing of various drug combinations without any preconceived “favorites,” according to Tyner. Among all pairings tested, including current standard treatments, the leukemia-breast cancer drug combination demonstrated the most promising outcomes.

“That really motivated us to dig deeper into why it works so well — and why it appears to overcome resistance seen with current therapy,” said Melissa Stewart, research assistant professor at OHSU and lead author of the study.

The research revealed a key mechanism behind the combination’s effectiveness. When AML cells were exposed only to venetoclax, they adapted by increasing protein production. However, adding palbociclib blocked this adaptive response, significantly hindering cancer cells’ survival ability.

Stewart highlighted the dramatic difference in their experimental models: “In this model, venetoclax alone didn’t extend survival at all — just as we’d expect based on the genetics. But with the combination, the majority of mice lived 11 to 12 months. In fact, one mouse was still alive when the study ended.”

This research provides crucial insights into the biological mechanisms underlying the improved outcomes from this novel drug combination, potentially paving the way for clinical trials with human patients.

The medical community has already made strides in AML treatment. Venetoclax, approved by the FDA in 2019, is commonly paired with azacitidine, another cancer medication. While this combination improved initial response rates and quality of life for patients, resistance to treatment remains nearly universal.

“Unfortunately, almost everyone will eventually have drug resistance,” Tyner noted. “This regimen has improved initial response rates and quality of life, but the five-year survival rate for AML is still only about 25% to 40%. We have a lot of work to do.”

These sobering statistics underscore the urgent need for more effective treatments. Despite advances in cancer therapy, AML remains particularly challenging to treat, with many patients experiencing relapse or developing resistance to standard therapies.

While the research team has compelling laboratory data supporting the efficacy of this new drug combination, they acknowledge they don’t yet have extensive clinical data from AML patients beyond a few anecdotal cases.

“So, the biggest limitation is also our desired next step — of testing this new drug combination in clinical trials,” Tyner said.

The potential impact of this research extends beyond improving survival rates. By targeting treatment-resistant forms of leukemia, this drug combination could significantly enhance quality of life for patients who currently have limited therapeutic options.

As clinical trials move forward, oncologists and patients alike will be watching closely to see if this promising laboratory finding translates into a breakthrough treatment that could reshape the standard of care for one of the most challenging forms of blood cancer.